Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

3 marketed · 7 in Phase 3

Quick facts

daptomycin and gentamicin
daptomycin (up to 14 days) · Infectious Disease
Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.
Semi-Synthetic Penicillin · Infectious Disease
Semi-synthetic penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Alviompan · Other
CB-183,315 · Infectious Disease
CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome.
CXA-201 · Infectious Disease
CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome.
CXA-201 and metronidazole · Infectious Disease
CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent.
Nafcillin (or equivalent) · Infectious Disease
Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Tedizolid Phophate · Infectious Diseases
Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit.
Vancomycin (or equivalent) · Infectious Diseases
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.

ADL5859 · Infectious Diseases
ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis.
CXA-101 · Infectious Diseases
CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition.

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: